The global coagulation market size was estimated to be USD 4.2 billion in 2023 and is expected to reach at USD 8.1 billion by 2033 with a CAGR of 7.2% during the forecast period 2023-2033. Increasing incidence of bleeding disorders, rising technological advancements, increasing surgical procedures, growing awareness and diagnosis of coagulation disorders, and increasing research and development activities will drive the market growth.
The accuracy, speed, and efficiency of coagulation testing have all improved as a result of technological and instrument advancements. Faster and more convenient testing has been made possible by the introduction of automated coagulation analyzers and point-of-care testing equipment, which has stimulated market expansion. For instance, Roche announced the release of their cobas tPA solution in August 2021, a highly sensitive diagnostic test that gauges a patient's tPA levels. This test aids in determining whether patients may benefit from thrombolytic therapy and gauging the severity of a stroke.
By product type, fibrinolytic agents was the highest revenue-grossing segment in the global coagulation market in 2022 owing to their critical role in the management of thrombotic disorders and the increasing adoption of fibrinolytic therapy in various healthcare settings. For instance, Abbott's new blood coagulation test, the Alinity sBTI, which aids in the monitoring of patients on direct oral anticoagulant (DOAC) therapy, obtained FDA clearance in March 2021. Coagulation factors will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the growing demand for replacement therapies in patients with inherited bleeding disorders, such as hemophilia, von Willebrand disease, and factor deficiencies.
By test type, prothrombin time (PT) tests was the highest revenue-grossing segment in the global coagulation market in 2022 owing to the widespread use of PT tests in various clinical settings, including hospitals, diagnostic laboratories, and point-of-care settings. For instance, Siemens Healthineers unveiled the Sysmex CS-2500i, its newest hemostasis system, in June 2021. This system delivers high-throughput coagulation testing with improved automation and turnaround times. Activated partial thromboplastin time tests will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the rising incidence of coagulation disorders, such as hemophilia, lupus anticoagulant, and von Willebrand disease, which necessitate regular monitoring of the intrinsic pathway of the coagulation cascade.
By end-user, hospitals was the highest revenue-grossing segment in the global coagulation market in 2022 owing to the significant volume of coagulation testing conducted in hospital settings and the wide range of coagulation-related procedures performed within these facilities. For instance, the GEM Premier ChemSTAT system, a cutting-edge platform for detecting blood gas, electrolytes, and coagulation parameters in critically ill patients, was introduced by Werfen's subsidiary Instrumentation Laboratory in January 2021. Research institutes will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the growing focus on research and development activities in the field of coagulation, driving the demand for specialized coagulation testing, innovative therapies, and cutting-edge technologies.
The accuracy, speed, and efficiency of coagulation testing have all improved as a result of technological and instrument advancements. Faster and more convenient testing has been made possible by the introduction of automated coagulation analyzers and point-of-care testing equipment, which has stimulated market expansion. For instance, Roche announced the release of their cobas tPA solution in August 2021, a highly sensitive diagnostic test that gauges a patient's tPA levels. This test aids in determining whether patients may benefit from thrombolytic therapy and gauging the severity of a stroke.
By product type, fibrinolytic agents was the highest revenue-grossing segment in the global coagulation market in 2022 owing to their critical role in the management of thrombotic disorders and the increasing adoption of fibrinolytic therapy in various healthcare settings. For instance, Abbott's new blood coagulation test, the Alinity sBTI, which aids in the monitoring of patients on direct oral anticoagulant (DOAC) therapy, obtained FDA clearance in March 2021. Coagulation factors will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the growing demand for replacement therapies in patients with inherited bleeding disorders, such as hemophilia, von Willebrand disease, and factor deficiencies.
By test type, prothrombin time (PT) tests was the highest revenue-grossing segment in the global coagulation market in 2022 owing to the widespread use of PT tests in various clinical settings, including hospitals, diagnostic laboratories, and point-of-care settings. For instance, Siemens Healthineers unveiled the Sysmex CS-2500i, its newest hemostasis system, in June 2021. This system delivers high-throughput coagulation testing with improved automation and turnaround times. Activated partial thromboplastin time tests will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the rising incidence of coagulation disorders, such as hemophilia, lupus anticoagulant, and von Willebrand disease, which necessitate regular monitoring of the intrinsic pathway of the coagulation cascade.
By end-user, hospitals was the highest revenue-grossing segment in the global coagulation market in 2022 owing to the significant volume of coagulation testing conducted in hospital settings and the wide range of coagulation-related procedures performed within these facilities. For instance, the GEM Premier ChemSTAT system, a cutting-edge platform for detecting blood gas, electrolytes, and coagulation parameters in critically ill patients, was introduced by Werfen's subsidiary Instrumentation Laboratory in January 2021. Research institutes will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the growing focus on research and development activities in the field of coagulation, driving the demand for specialized coagulation testing, innovative therapies, and cutting-edge technologies.
Global Coagulation, By Region (USD Billion)
North America was the highest revenue-grossing segment in the global coagulation market in 2022 owing to the well-established healthcare infrastructure, high prevalence of coagulation disorders, and strong adoption of advanced coagulation testing and management practices. For instance, Sysmex Corporation announced the release of the CS-2400i, a new completely automated blood coagulation analyzer, in November 2021. The system provides sophisticated capabilities for high-throughput testing and increased effectiveness in coagulation laboratories. Asia Pacific will be the fastest revenue-grossing segment in the global coagulation market in 2022 owing to the increasing prevalence of coagulation disorders, improving healthcare infrastructure, and a growing focus on early diagnosis and treatment.Global Coagulation Factors Market (USD Billion), 2023 & 2033
This comprehensive research report focuses on the global and regional market size and forecasts from 2022 to 2033.Report Scope:
- Base Year: 2022
- Forecast Period: 2023-2033
- Study Coverage
- Market Forecast by Product type, Test type, End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Coagulation Market Report 2022-2033
Coagulation Market Analysis & Forecast by Product Type 2022-2033 (Revenue USD Bn)
- Coagulation Analyzers
- Consumables
- Coagulation Factors
- Fibrinolytic Agents
Coagulation Market Analysis & Forecast by Test Type 2022-2033 (Revenue USD Bn)
- Prothrombin Time (PT) Tests
- Activated Partial Thromboplastin Time Tests
- D-Dimer Tests
- Platelet Function Tests
Coagulation Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Bn)
- Hospitals
- Diagnostic Laboratories
- Research Institutes
Coagulation Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin American
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Coagulation Market: Product Type Estimates & Trend Analysis
8. Coagulation Market: Test Type Estimates & Trend Analysis
9. Coagulation Market: End-user Estimate & Trend Analysis
10. Regional Market Analysis
11. North America Coagulation Market
12. Europe Global Coagulation Market
13. Asia Pacific Global Coagulation Market
14. Latin America Global Coagulation Market
15. MEA Global Coagulation Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- CryoLife, Inc
- Baxter International, Inc
- Cohera Medical, Inc
- C.R. Bard, Inc
- Ethicon, Inc. [J&J]
- Cardinal Health
- Integra LifeSciences Holdings Corporation
- Mallinckrodt plc
- B. Braun Melsungen AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 4.2 Billion |
| Forecasted Market Value ( USD | $ 8 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
